Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ocular Surface Disease Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

NCT04354545
View directory record Official record
Conditions
Glaucoma, Ocular Surface Disease
Interventions
Xiidra (Lifitegrast ophthalmic solution) 5%
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Not applicable Interventional

Changes in Tear Osmolarity Over Time With Sustained Use of TheraTears

NCT02100787
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
TheraTears lubricating drops
Other
Lead sponsor
Jenkins Eye Care
Other
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

NCT01393132
View directory record Official record
Conditions
Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease
Interventions
Thymosin Beta 4 eye drops, Vehicle Control
Drug
Lead sponsor
Michigan Cornea Consultants, PC
Other
Eligibility
18 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Jul 20, 2026, 6:42 PM EDT
Withdrawn Not applicable Interventional

Omega 3 Supplementation and Ocular Surface Disease in Glaucoma

NCT01630551
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
Fishoil supplement, Olive Oil
Dietary Supplement
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Dry Eye Treatments on the Ocular Surface

NCT01797822
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Syndrome
Interventions
Dexamethasone, Artificial tear
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 20, 2026, 6:42 PM EDT
Not yet recruiting No phase listed Observational

Lacrifill for Ocular Surface Optimization in Cataract Surgery

NCT07648095
View directory record Official record
Conditions
Cataract
Interventions
Lacrifill Canalicular Filler
Device
Lead sponsor
The Eye Institute of West Florida
Other
Eligibility
40 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Largo, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

NCT00799682
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Xalatan, Travatan Z
Drug
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
5
States / cities
East Meadow, New York • Lynbrook, New York • Rockville Centre, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Early Phase 1 Interventional

Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

NCT05204329
View directory record Official record
Conditions
Mesenchymal Stromal Cells, Cornea, Corneal Defect, Corneal Epithelium Defect
Interventions
MSC Secretome Eye Drops
Biological
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Completed No phase listed Observational

Immune Indicators of Uveitis

NCT00089739
View directory record Official record
Conditions
GITR, GITR Ligand, Uveitis, Immunosuppression, Suppressor of Cytokine Secretion
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 20, 2026, 6:42 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye

NCT06364657
View directory record Official record
Conditions
Sjogren's Syndrome, Dry Eye, Neurotrophic Keratitis
Interventions
Eye Exam
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimization of the Ocular Surface Prior to Cataract Surgery Using PROKERA

NCT05148507
View directory record Official record
Conditions
Cataract, Dry Eye Syndromes, Cataract Senile, Dry Eye
Interventions
PROKERA
Device
Lead sponsor
Jeff Wongskhaluang
Other
Eligibility
18 Years to 100 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Olathe, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Early Phase 1 Interventional

The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

NCT04792580
View directory record Official record
Conditions
Graft-versus-host-disease, Ocular Graft-versus-host Disease
Interventions
Lifitegrast 5% Ophthalmic Solution, Placebo
Drug
Lead sponsor
Richard W Yee, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2024 · Synced Jul 20, 2026, 6:42 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Novel Use of Restasis and PROSE Devices

NCT04735510
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
cyclosporine ophthalmic emulsion 0.05%
Drug
Lead sponsor
Boston Sight
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 4 Interventional Results available

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT01253902
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
bimatoprost ophthalmic solution 0.01%, travoprost ophthalmic solution 0.004%, latanoprost ophthalmic solution 0.005%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Jul 20, 2026, 6:42 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra

NCT04120987
View directory record Official record
Conditions
Dry Eye
Interventions
Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Bucci Laser Vision Institute
Other
Eligibility
60 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 20, 2026, 6:42 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza®) in the Management of Clinically Significant Dry Eye

NCT04498468
View directory record Official record
Conditions
Dry Eye
Interventions
Sustained Release Dexamethasone, 0.4 mg, E-Caprolactone-L-Lactide copolymer (PCL) punctal plug
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Jul 20, 2026, 6:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Validation of Computerized Vision-Targeted Quality-of-Life Questionnaires

NCT00678860
View directory record Official record
Conditions
Eye Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 20, 2026, 6:42 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure

NCT06080438
View directory record Official record
Conditions
Tears; Excess, Eyelid Spasm
Interventions
Botulinum toxin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Jul 20, 2026, 6:42 PM EDT
Completed No phase listed Observational

Screening for Research Subjects With Anterior Segment Diseases

NCT00088348
View directory record Official record
Conditions
Eye Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 20, 2026, 6:42 PM EDT
Withdrawn Phase 2 Interventional

OSIG-eye Drops Treatment for Dry Eye Disease

NCT04510428
View directory record Official record
Conditions
Dry Eye
Interventions
Ocular Surface Immune Globulin (OSIG), Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease

NCT01254370
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Ocular Surface Disease
Interventions
Latanoprost, Travatan Z
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Jul 20, 2026, 6:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ocular Surface Immune Response in Dry Eye Disease

NCT02042820
View directory record Official record
Conditions
Dry Eye Disease
Interventions
In vivo confocal microscopy (IVCM)
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Jul 20, 2026, 6:42 PM EDT
Not listed Early Phase 1 Interventional

Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections

NCT03571100
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Vascular Diseases, Proliferative Retinopathy, Retina Vein Occlusion
Interventions
Chlorhexidine, Povidine-Iodine
Drug
Lead sponsor
MidAtlantic Retina
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jul 20, 2026, 6:42 PM EDT